BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

INNOVIVE Pharmaceuticals Presents Phase I Data on INNO-406 for Treatment of Gleevec-Resistant or Intolerant Chronic Myelogenous Leukemia at American Society of Hematology


12/10/2007 11:35:43 AM

ATLANTA--(BUSINESS WIRE)--INNOVIVE Pharmaceuticals, Inc. (OTCBB: IVPH) today presented clinical data from the first part of a two-part Phase I study of its drug candidate INNO-406, a potent, oral, dual Bcr-Abl and Lyn-kinase inhibitor in patients with Chronic Myelogenous Leukemia (CML). In the study, INNO-406 was shown to be well tolerated and demonstrated activity in patients with CML who are intolerant or resistant to imatinib (GleevecĀ®) and multiple second generation tyrosine kinase inhibitors. The data were presented today at an oral presentation at the 49th American Society of Hematology Annual Meeting in Atlanta.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->